GSK (GSK) Competitors

GBX 1,843 -30.25 (-1.61%)

As of 05/8/2026 12:35 PM Eastern

GSK vs. AZN, ITH, SOPH, INDV, and HCM

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to AstraZeneca?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

64.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.0% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by insiders. Comparatively, 0.2% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.4%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.6%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
GSK	17.78%	35.78%	9.56%

AstraZeneca has a beta of 0.223, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.298, indicating that its share price is 70% less volatile than the S&P 500.

In the previous week, GSK had 6 more articles in the media than AstraZeneca. MarketBeat recorded 12 mentions for GSK and 6 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.62 beat GSK's score of 0.25 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.42	£8.71B	£664.00	20.10
GSK	£32.78B	2.24	£2.50B	£142.10	12.97

AstraZeneca currently has a consensus target price of £153.33, suggesting a potential upside of 14.91%. GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 10.38%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

AstraZeneca beats GSK on 10 of the 18 factors compared between the two stocks.

How does GSK compare to Ithaca Energy?

Ithaca Energy (LON:ITH) and GSK (LON:GSK) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

GSK has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ithaca Energy	£2.95B	1.47	£230.29M	-£5.10	N/A
GSK	£32.78B	2.24	£2.50B	£142.10	12.97

GSK has a net margin of 17.78% compared to Ithaca Energy's net margin of -2.85%. GSK's return on equity of 35.78% beat Ithaca Energy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ithaca Energy	-2.85%	-3.13%	0.18%
GSK	17.78%	35.78%	9.56%

In the previous week, GSK had 10 more articles in the media than Ithaca Energy. MarketBeat recorded 12 mentions for GSK and 2 mentions for Ithaca Energy. Ithaca Energy's average media sentiment score of 1.38 beat GSK's score of 0.25 indicating that Ithaca Energy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ithaca Energy	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.6% of Ithaca Energy shares are owned by institutional investors. Comparatively, 45.0% of GSK shares are owned by institutional investors. 0.2% of Ithaca Energy shares are owned by insiders. Comparatively, 0.2% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ithaca Energy has a beta of 0.353, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.298, indicating that its share price is 70% less volatile than the S&P 500.

Ithaca Energy currently has a consensus target price of GBX 205, suggesting a potential downside of 21.99%. GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 10.38%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Ithaca Energy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ithaca Energy	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Ithaca Energy pays an annual dividend of GBX 30.31 per share and has a dividend yield of 11.5%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.6%. Ithaca Energy pays out -594.3% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ithaca Energy is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

GSK beats Ithaca Energy on 12 of the 17 factors compared between the two stocks.

How does GSK compare to Sophos Group plc (SOPH.L)?

GSK (LON:GSK) and Sophos Group plc (SOPH.L) (LON:SOPH) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

GSK has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£32.78B	2.24	£2.50B	£142.10	12.97
Sophos Group plc (SOPH.L)	£726.90M	0.00	N/A	£1.70	N/A

GSK has a net margin of 17.78% compared to Sophos Group plc (SOPH.L)'s net margin of 0.00%. GSK's return on equity of 35.78% beat Sophos Group plc (SOPH.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.78%	35.78%	9.56%
Sophos Group plc (SOPH.L)	N/A	N/A	N/A

In the previous week, GSK had 12 more articles in the media than Sophos Group plc (SOPH.L). MarketBeat recorded 12 mentions for GSK and 0 mentions for Sophos Group plc (SOPH.L). GSK's average media sentiment score of 0.25 beat Sophos Group plc (SOPH.L)'s score of 0.00 indicating that GSK is being referred to more favorably in the media.

Company	Overall Sentiment
GSK	Neutral
Sophos Group plc (SOPH.L)	Neutral

45.0% of GSK shares are owned by institutional investors. 0.2% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GSK presently has a consensus target price of GBX 2,034.29, suggesting a potential upside of 10.38%. Given GSK's stronger consensus rating and higher possible upside, research analysts plainly believe GSK is more favorable than Sophos Group plc (SOPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Sophos Group plc (SOPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.6%. Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. GSK pays out 46.4% of its earnings in the form of a dividend. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

GSK beats Sophos Group plc (SOPH.L) on 13 of the 15 factors compared between the two stocks.

How does GSK compare to Indivior?

GSK (LON:GSK) and Indivior (LON:INDV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

45.0% of GSK shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 0.2% of GSK shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£32.78B	2.24	£2.50B	£142.10	12.97
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.6%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. GSK pays out 46.4% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has a net margin of 17.78% compared to Indivior's net margin of 14.30%. GSK's return on equity of 35.78% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.78%	35.78%	9.56%
Indivior	14.30%	-41.70%	2.37%

In the previous week, GSK had 10 more articles in the media than Indivior. MarketBeat recorded 12 mentions for GSK and 2 mentions for Indivior. GSK's average media sentiment score of 0.25 beat Indivior's score of 0.00 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GSK has a beta of 0.298, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Summary

GSK beats Indivior on 15 of the 18 factors compared between the two stocks.

How does GSK compare to HUTCHMED?

HUTCHMED (LON:HCM) and GSK (LON:GSK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

20.4% of HUTCHMED shares are held by institutional investors. Comparatively, 45.0% of GSK shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 0.2% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GSK has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£548.51M	3.06	-£52.98M	£53.00	3.68
GSK	£32.78B	2.24	£2.50B	£142.10	12.97

GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 10.38%. Given GSK's stronger consensus rating and higher possible upside, analysts clearly believe GSK is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, GSK had 10 more articles in the media than HUTCHMED. MarketBeat recorded 12 mentions for GSK and 2 mentions for HUTCHMED. GSK's average media sentiment score of 0.25 beat HUTCHMED's score of -0.23 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has a net margin of 104.77% compared to GSK's net margin of 17.78%. HUTCHMED's return on equity of 41.38% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	104.77%	41.38%	-5.90%
GSK	17.78%	35.78%	9.56%

HUTCHMED has a beta of 0.453, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.298, meaning that its stock price is 70% less volatile than the S&P 500.

Summary

GSK beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£73.57B	£71.95B	£6.25B	£2.77B
Dividend Yield	3.66%	2.42%	2.78%	6.15%
P/E Ratio	12.97	25.14	20.64	366.07
Price / Sales	2.24	142.49	534.02	88,619.89
Price / Cash	8.15	16.19	43.29	27.89
Price / Book	5.59	3.47	9.98	7.72
Net Income	£2.50B	£3.18B	£3.54B	£5.89B
7 Day Performance	-3.05%	-2.03%	3.50%	63.96%
1 Month Performance	-14.29%	-3.79%	4.17%	4.05%
1 Year Performance	33.79%	22.40%	41.85%	87.37%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.6289 of 5 stars	GBX 1,843 -1.6%	GBX 2,034.29 +10.4%	N/A	£73.57B	£32.78B	12.97	70,212	Analyst Forecast
AZN AstraZeneca	3.8048 of 5 stars	£137.76 -1.4%	£152.50 +10.7%	N/A	£213.64B	£58.74B	21.06	83,500	Positive News Analyst Forecast
ITH Ithaca Energy	1.0071 of 5 stars	GBX 270.80 +1.5%	GBX 205 -24.3%	N/A	£4.47B	£2.95B	N/A	220	News Coverage
SOPH Sophos Group plc (SOPH.L)	N/A	N/A	N/A	N/A	£2.99B	£726.90M	341.41	520
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	N/A	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GSK) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors